Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3345248

CC(C)CCN1CCc2cc(-c3cccc(C(N)=O)c3)ccc2C1.O=C(O)C(F)(F)F

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 4/20 0.48
DPP7 Q9UHL4 3/20 0.48
DPP8 Q6V1X1 2/20 0.48
DPP9 Q86TI2 1/20 0.48
PRMT5 O14744 4/20 0.47
WDR77 Q9BQA1 4/20 0.47
OPRM1 P35372 5/20 0.46
OPRD1 P41143 5/20 0.46
OPRK1 P41145 5/20 0.46
RIPK1 Q13546 1/20 0.43
DRD3 P35462 4/20 0.42
DRD2 P14416 3/20 0.42
HTR1A P08908 2/20 0.40
HTR2B P41595 2/20 0.40
CHRM2 P08172 1/20 0.40
CHRM3 P20309 1/20 0.40
DRD4 P21917 1/20 0.40
ADRA1D P25100 1/20 0.40
HTR2C P28335 1/20 0.40
ADRA1A P35348 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12607804 0.93 PRMT5 (0.52) DPP4DPP8PRMT5WDR77OPRM1
Trifluoroacetic Acid SCHEMBL1791141 0.86 OPRM1 (0.54) PRMT5WDR77OPRM1OPRD1OPRK1
Trifluoroacetic Acid SCHEMBL1786436 0.80 ENPP2 (0.47) DPP4DPP7DPP8DPP9PRMT5
SCHEMBL3345252 0.80 NAMPT (0.47) PRMT5WDR77DRD3HTR1AHTR2B
SCHEMBL12607826 0.79 OPRM1 (0.59) PRMT5WDR77OPRM1OPRD1OPRK1
SCHEMBL12607818 0.77 TMEM97 (0.62) PRMT5WDR77OPRM1OPRD1OPRK1
Hydrochloric Acid SCHEMBL1785554 0.76 TMEM97 (0.61) PRMT5WDR77OPRM1OPRD1OPRK1
Trifluoroacetic Acid SCHEMBL1783579 0.75 DPP4 (0.45) DPP4DPP7DPP8DPP9PRMT5
SCHEMBL3699858 0.73 OPRM1 (0.68) OPRM1OPRD1OPRK1DRD3DRD2
SCHEMBL12607816 0.72 ENPP2 (0.52) PRMT5WDR77OPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors GLAXOSMITHKLINE LLC 2014-10-30 US disclosed
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS IGNAR DIANE MICHELE 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS OPRL1, OPRD1, OPRK1 DPP4 1431/4885DPP7 1333/4885DPP8 2313/4885
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors OPRL1, OPRM1, OPRK1 DPP4 1228/4885DPP7 1096/4885DPP8 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.